Metabolic regulation by the intestinal metformin-AMPK axis

AMP-activated protein kinase (AMPK) mediates the glucose-lowering effect of the antidiabetic agent metformin, but the sites of action remain unclear. In the March issue of Nature Communications, Zhang and colleagues reported that intestinal epithelium-specific AMPKα1 knockout mice fail to respond to...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 13; no. 1; p. 2851
Main Authors Zhang, Song-Yang, Lam, Tony K T
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 23.05.2022
Nature Publishing Group UK
Nature Portfolio
Subjects
AMP-activated protein kinase
Antidiabetics
Comment
Diabetes mellitus
Epithelium
Homeostasis
Intestinal microflora
Intestine
Kinases
Metabolism
Metformin
Microbiomes
Phosphates
Online AccessGet full text

Cover

More Information
Summary:AMP-activated protein kinase (AMPK) mediates the glucose-lowering effect of the antidiabetic agent metformin, but the sites of action remain unclear. In the March issue of Nature Communications, Zhang and colleagues reported that intestinal epithelium-specific AMPKα1 knockout mice fail to respond to metformin and exhibit disruption in metabolic homeostasis secondary to changes in the gut microbiome. This highlights a therapeutic potential of targeting intestinal AMPK for diabetes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-022-30477-3